

TRANSMITTAL FORM

Application Serial Number	09/256,156
Filing Date	February 24, 1999
First Named Inventor	Gillies
Group Art Unit	1646
Examiner Name	J. F. Murphy
Attorney Docket No.	LEX-003

TECH CENTER 1600/2900
RECEIVED
03 MAY 1 2003
1: PM

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form 	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <ul style="list-style-type: none"> <input type="checkbox"/> Formal Drawing(s) 	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <ul style="list-style-type: none"> <input type="checkbox"/> Appeal Brief (in triplicate)
<input type="checkbox"/> Amendment and Response <ul style="list-style-type: none"> <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final 	<input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <ul style="list-style-type: none"> <input type="checkbox"/> Associate Power of Attorney 	<input type="checkbox"/> Status Inquiry <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Petition for Extension of Time	<input type="checkbox"/> Terminal Disclaimer <ul style="list-style-type: none"> <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application 	<input type="checkbox"/> Certificate of Hand Delivery <ul style="list-style-type: none"> <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8
<input checked="" type="checkbox"/> Information Disclosure Statement <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Form PTO-1449 <input type="checkbox"/> Copies of IDS Citations (A2-A54; B7-B82; C142) 	<input type="checkbox"/> Small Entity Statement <ul style="list-style-type: none"> <input type="checkbox"/> CD(s) for large table or computer program 	<input type="checkbox"/> Additional Enclosure(s) <ul style="list-style-type: none"> <i>(please identify below)</i>
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Amendment After Allowance <ul style="list-style-type: none"> <input type="checkbox"/> Request for Certificate of Correction 	
<input type="checkbox"/> Sequence Listing submission <ul style="list-style-type: none"> <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above 	<input type="checkbox"/> Certificate of Correction (in duplicate)	

05/02/2003 GAN:NY 00000 Copies of IDS Citations (A2-A54; B7-B82; C142)

RECEIVED

MAY 05 2003

TECH CENTER 1600/2900

CORRESPONDENCE ADDRESS

Direct all correspondence to:

Patent Administrator
Testa, Hurwitz & Thibeault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,


Pat R.H. Wall

Patrick R.H. Waller
Attorney for Applicant
Testa, Hurwitz & Thibeault, LLP
High Street Tower
125 High Street
Boston, MA 02110

FEE TRANSMITTAL

FY 2003

<i>Complete if Known</i>	
Application Serial Number	09/256,156
Filing Date	February 24, 1999
First Named Inventor	Gillies
Group Art Unit	1646
Examiner Name	J. F. Murphy
Attorney Docket No.	LEX-003

METHOD OF PAYMENT					FEE CALCULATION (continued)			
1. <input checked="" type="checkbox"/> Payment Enclosed: <input checked="" type="checkbox"/> Check <input type="checkbox"/> Money Order <input type="checkbox"/> Other					3. ADDITIONAL FEES			
2. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 20-0531. <input type="checkbox"/> Required Fees (copy of this sheet enclosed). <input checked="" type="checkbox"/> Additional fee required under 37 CFR 1.16 and 1.17. <input checked="" type="checkbox"/> Overpayment Credit.					Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description	Fee Paid
3. <input type="checkbox"/> Applicant claims small entity status.					130	65	Surcharge - late filing fee or oath	
					50	25	Surcharge - late provisional filing fee or cover sheet	
					130	130	Non-English specification	
					2,520	2,520	Request for ex parte reexamination	
					110	55	Extension for reply within first month	
					410	205	Extension for reply within second month	
					930	465	Extension for reply within third month	
					1450	725	Extension for reply within fourth month	
					1970	985	Extension for reply within fifth month	
					320	160	Notice of Appeal	
					320	160	Filing a brief in support of an appeal	
					280	140	Request for oral hearing	
					130	130	Petitions to the Commissioner	
					180	180	Submission of Information Disclosure Statement	180.00
					750	375	Filing a submission after final rejection (37 CFR 1.129(a))	
					750	375	For each additional invention to be examined (37 CFR 1.129(b))	
					100	100	Certificate of Correction for applicant's error	
					Other fee (Specify)		RECEIVED	
					Other fee (Specify)		MAY 05 2003	
							TECH CENTER 1600/2	
1. FILING FEE					2. AMENDMENT CLAIM FEES			
Large Entity Fee (\$)					Claims Highest No. Remaining Previously After Amend. Present Paid For			
750 Utility filing fee 330 Design filing fee 160 Provisional filing fee					Rate Number Filed Number Extra			
					Amount x \$ 18.00 = x \$ 84.00 = \$280.00 =			
Total Claims - 20 = Independent Claims - 3 =					TOTAL: SMALL ENTITY DISCOUNT: SUBTOTAL (1) (\$)			
<input type="checkbox"/> Multiple Dependent Claim(s), if any					0.00			
					SUBTOTAL (1) (\$)			
					0.00			
2. AMENDMENT CLAIM FEES					SUBTOTAL (3) (\$)			
Claims Remaining After Amend. Highest No. Previously Paid For					Present Extra			
Total 13 - 44 = 0 Indep. 3 - 4 = 0					Rate x \$ 18.00 = 0.00 x \$ 84.00 = 0.00			
<input type="checkbox"/> First Presentation of Multiple Dep. Claim					Fee Paid + \$280.00 =			
					TOTAL: (\$)			
TOTAL: SMALL ENTITY DISCOUNT: SUBTOTAL (2) (\$)					0.00			
					SUBTOTAL (1) (\$)			
					SUBTOTAL (2) (\$)			
					SUBTOTAL (3) (\$)			
					TOTAL (\$)			
CORRESPONDENCE ADDRESS					SIGNATURE BLOCK			
Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thibeault, LLP High Street Tower-125 High Street Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100					Respectfully submitted,  Patrick R.H. Waller Attorney for the Applicants Testa, Hurwitz & Thibeault, LLP High Street Tower-125 High Street Boston, MA 02110			

PATENT
Attorney Docket No. LEX-003
400614


RECEIVED
TECH CENTER 1600/2900
MAY - 1 PM 1:23
2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies et al.
SERIAL NO.: 09/256,156 GROUP NO.: 1646
FILING DATE: February 24, 1999 EXAMINER: J. F. Murphy
TITLE: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being hand delivered to Group Art Unit No. 1646 at the United States Patent and Trademark Office in 3 boxes addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, to the attention of Examiner Joseph F. Murphy, on this 1st day of May, 2003.



Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RECEIVED

MAY 05 2003

Sir:


TECH CENTER 1600/2900

Submitted herewith is/are:

Transmittal Form (1 page); Fee Transmittal Form (1 page); Supplemental Information Disclosure Statement (2 pages); Supplemental Form PTO-1449 (15 pages); copies of references A2-A54, B7-B82, & C10-C142; a check in the amount of \$180.00; and a return receipt postcard.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies et. al

SERIAL NO.: 09/256,156 GROUP NO.: 1646

FILING DATE: February 24, 1999 EXAMINER: J. F. Murphy

TITLE: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RECEIVED
TECH CENTER 1600/2900

03 MAY - 1 PM 1:23

RECEIVED

MAY 05 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filng date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- the requisite Statement is below, **OR**
- the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

Supplemental Information Disclosure Statement

Serial No. 09/256,156

Page 2 of 2


(3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee, AND**

the requisite Statement is below, **AND**

the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Patrick R.H. Waller, Ph.D.

Attorney for Applicant(s)

Testa, Hurwitz, & Thibeault, LLP

High Street Tower

125 High Street

Boston, Massachusetts 02110

Date: April 29, 2003

Reg. No. 41,418

Tel. No.: (617) 248-7240

Fax No.: (617) 248-7100

2614555

RECEIVED
TECH CENTER 1600/2900

03 MAY -1 PM 1:23

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-003	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies et al.	
		SERIAL NO.: 09/256,156	
		FILING DATE: February 24, 1999	
		GROUP: 1646	

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A2	07/348,237	5/5/89	Rosenblum et al.			
	A3	4,196,265	4/1/80	Koprowski et al.			
	A4	4,469,797	9/4/84	Albarella			
	A5	4,676,980	6/30/87	Segal et al.			
	A6	4,816,567	3/28/89	Cabilly et al.			
	A7	4,946,778	8/7/90	Ladner et al.			RECEIVED
	A8	5,073,627	12/17/91	Curtis et al.			MAY 05 2003
	A9	5,114,711	5/19/92	Bell et al.			
	A10	5,116,964	5/26/92	Capon et al.			TECH CENTER 1600/2900
	A11	5,199,942	4/6/93	Gillis			
	A12	5,225,538	7/6/93	Capon et al.			
	A13	5,225,539	7/6/93	Winter			
	A14	5,258,498	11/2/93	Huston et al..			
	A15	5,314,995	5/24/94	Fell, Jr. et al.			
	A16	5,349,053	9/20/94	Landolfi			
	A17	5,359,035	10/25/94	Habermann			
	A18	5,514,582	5/7/96	Capon et al.			
	A19	5,538,866	7/23/96	Israeli et al.			
	A20	5,541,087	7/30/96	Lo et al.			
	A21	5,543,297	8/6/96	Cromlish, et al.			
	A22	5,552,524	09/03/96	Basinski et al.			
	A23	5,585,089	12/17/96	Queen et al.			
	A24	5,609,846	3/11/97	Goldenberg			
	A25	5,639,725	6/17/97	O'Reilly et al.			
	A26	5,650,150	7/22/97	Gillies			
	A27	5,650,492	7/22/97	Gately, et al.			
	A28	5,667,776	9/16/97	Zimmerman et al.			
EXAMINER				DATE CONSIDERED			

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies et al.			
				SERIAL NO.: 09/256,156			
				FILING DATE: February 24, 1999 GROUP: 1646			

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A29	5,691,309	11/25/97	Basinski et al.			
	A30	5,709,859	1/20/98	Aruffo et al.			
	A31	5,719,266	02/17/98	DiMarchi et al.			
	A32	5,723,125	3/3/98	Chang et al.			
	A33	5,726,044	3/10/98	Lo et al.			
	A34	5,728,552	3/17/98	Fujisawa et al.			
	A35	5,733,876	3/31/98	O'Reilly et al.			
	A36	5,756,461	05/26/98	Stephens			
	A37	5,759,551	6/2/98	Ladd et al.			
	A38	5,770,195	6/23/98	Hudziak et al.			MAY 05 2003
	A39	5,800,810	9/1/98	Doyle et al.			
	A40	5,827,516	10/27/98	Urban et al.			
	A41	5,837,682	11/17/98	Folkman et al.			
	A42	5,843,423	12/1/98	Lyman et al.			
	A43	5,854,205	12/29/98	O'Reilly et al.			
	A44	5,858,347	1/12/99	Bauer et al.			
	A45	5,885,795	3/23/99	O'Reilly et al.			
	A46	5,886,178	3/23/99	Allen et al.			
	A47	5,994,126	11/30/99	Steinman et al.			
	A48	6,080,409	6/27/00	Laus et al.			
	A49	6,086,875	7/11/00	Blumberg et al.			
	A50	6,100,387	8/8/00	Herrmann et al.			
	A51	6,169,070	1/2/01	Chen et al.			
	A52	6,171,588	1/9/01	Carron et al.			
	A53	6,277,375 B1	8/21/01	Ward			
	A54	6,406,689 B1	6/18/02	Falkenberg et al.			
EXAMINER				DATE CONSIDERED			

RECEIVED

MAY 05 2003
TECH CENTER 1600/2900

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies et al.					
				SERIAL NO.: 09/256,156					
				FILING DATE: February 24, 1999 GROUP: 1646					
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILIN G DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B7	0 158 198	10/16/85	EP					Y
	B8	0 211 769	2/25/87	EP					Y
	B9	0 256 714	2/24/88	EP				<i>RECEIVED MAY 05 2003 TECH CENTER 1600/2900</i>	Y
	B10	0 294 703	12/14/88	EP					Y
	B11	0 308 936	3/29/89	EP					Y
	B12	0 314 317	5/3/89	EP					Y
	B13	0 319 012	6/7/89	EP					Y
§	B14	0 326 120	4/15/98	EP					Y
	B15	0 350 230	1/10/90	EP					Y
	B16	0 375 562	6/27/90	EP					Y
	B17	0 396 387	11/7/90	EP					Y
	B18	0 439 095	7/31/91	EP					Y
	B19	0 511 747	11/4/92	EP					Y
	B20	0 601 043	11/25/98	EP					Y
	B21	0 706 799	4/17/96	EP					Y
	B22	0 790 309	8/20/97	EP					Y
	B23	21725/88	3/23/89	AU					Y
	B24	93100115.3	7/14/93	CN				B78 is English abstract	N
	B25	37 12985	11/3/88	DE				B79 is English abstract; A50 is English counterpart	N
	B26	2 292 382	2/21/96	GB					Y
	B27	63-267278	11/4/88	JP				B80 is English abstract	N
	B28	63-267296	11/4/88	JP				B81 is English abstract; B82 is English counter part	N
	B29	WO 86/01533	3/13/86	PCT					Y
EXAMINER					DATE CONSIDERED				

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003					
SUPPLEMENTAL INFORMATION				APPLICANT(S): Gillies et al.					
DISCLOSURE STATEMENT				SERIAL NO.: 09/256,156					
				FILING DATE: February 24, 1999					
				GROUP: 1646					

RECEIVED
MAY 05 2003
TECH CENTER
600/2900

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILIN G DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B30	WO 88/00052	1/14/88	PCT					Y
	B31	WO 88/09344	12/1/88	PCT					Y
	B32	WO 89/02922	4/6/89	PCT					Y
	B33	WO 89/09620	10/19/89	PCT				Abstract in English	N
	B34	WO 90/03801	4/19/90	PCT					Y
	B35	WO 91/00360	1/10/91	PCT					Y
	B36	WO 91/04329	04/04/91	PCT					Y
	B37	WO 91/08298	6/13/91	PCT					Y
	B38	WO 91/13166	9/5/91	PCT					Y
	B39	WO 91/14438	10/3/91	PCT					Y
	B40	WO 92/02240	2/20/92	PCT					Y
	B41	WO 92/08801	5/29/92	PCT					Y
	B42	WO 92/16562	10/1/92	PCT					Y
	B43	WO 93/03157	2/18/93	PCT					Y
	B44	WO 93/10229	5/27/93	PCT					Y
	B45	WO 95/21258	8/10/95	PCT					Y
	B46	WO 95/28427	10/26/95	PCT					Y
	B47	WO 95/31483	11/23/95	PCT					Y
	B48	WO 96/04388	02/15/96	PCT					Y
	B49	WO 96/05309	2/22/96	PCT					Y
	B50	WO 96/08570	3/21/96	PCT					Y
	B51	WO 96/31526	10/10/96	PCT					Y
	B52	WO 97/00317	1/3/97	PCT					Y

EXAMINER

DATE CONSIDERED

RECEIVED
MAY 05 2003
TECH CENTER 1600
2900

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies et al.					
				SERIAL NO.: 09/256,156					
				FILING DATE: February 24, 1999 GROUP: 1646					
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B53	WO 97/15666	5/1/97	PCT					Y
	B54	WO 97/24137	7/10/97	PCT					Y
	B55	WO 97/24440	7/10/97	PCT					Y
	B56	WO 97/26335	7/24/97	PCT					Y
	B57	WO 97/30089	8/21/97	PCT					Y
	B58	WO 97/33619	9/18/97	PCT					Y
	B59	WO 97/34631	9/25/97	PCT					Y
	B60	WO 98/00127	1/8/98	PCT					Y
	B61	WO 98/06752	2/19/98	PCT					Y
	B62	WO 98/28427	7/2/98	PCT					Y
	B63	WO 98/30706	7/16/98	PCT					Y
	B64	WO 98/46257	10/22/98	PCT					Y
	B65	WO 98/59244	12/30/98	PCT					Y
	B66	WO 99/02709	01/21/99	PCT					Y
	B67	WO 99/03887	01/28/99	PCT					Y
	B68	WO 99/29732	6/17/99	PCT					Y
	B69	WO 99/43713	9/2/99	PCT					Y
	B70	WO 99/52562	10/21/99	PCT					Y
	B71	WO 99/53958	10/28/99	PCT					Y
	B72	WO 99/62944	12/09/99	PCT					Y
	B73	WO 00/11033	3/2/00	PCT					Y
	B74	WO 00/34317	06/15/00	PCT					Y
	B75	WO 00/40615	7/13/00	PCT					Y
EXAMINER					DATE CONSIDERED				

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999				
<i>RECEIVED MAY 05 2003 TECH CENTER 1600/2900 GROUP 6</i>									
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B76	WO 00/69913	11/23/02	PCT					Y
	B77	WO 01/07081	2/1/01	PCT					Y
	B78	93100115.3	7/14/93	CN				English abstract of B24	Y
	B79	37 12985	11/3/88	DE				English abstract of B25	Y
	B80	63-267278	11/4/88	JP				English abstract of B27	Y
	B81	63-267296	11/4/88	JP				English abstract of B28	Y
	B82	0 237 019	9/16/87	EP				English counterpart of B28	Y
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	C10	Abaza et al., (1992) "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization" <u>Journal of Protein Chemistry</u> , Vol. 11, No. 5: pp. 433-444.							
	C11	Abstract XP-002116766, (1996) "Prostaglandins, their inhibitors and cancer" <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , Vol. 54, No. 2, pp. 83-94.							
	C12	Arenberg et al. (1996) "Interferon- γ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , Vol. 184, pp. 981-992.							
	C13	Bacha et al., (1988). "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein", <u>J. Experimental Medicine</u> , Vol. 167, pp. 612-622							
	C14	Bachelot et al., (March 1998) "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo", <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , Vol. 39, pp. 271, Abstract #1856.							
	C15	Barnett et al. (1994) "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.							
	C16	Baselga, et al (1998) "Recombinant Humanized Anti-HER2 Antibody (Herceptin TM) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/neu Overexpressing Human Breast Cancer Xenografts." <u>Cancer Research</u> , Vol. 58, pp. 2825-2831.							
EXAMINER					DATE CONSIDERED				

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP: 1646
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C17	Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , Vol. 5, No. 12, pp. 4259-4263.	
C18	Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 2702-2707.	
C19	Beutler et al., (1988) "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator", <u>Ann. Rev. Biochem.</u> , Vol. 57, pp. 505-518.	
C20	Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins" <u>Cancer Research</u> , Vol. 45, pp. 1214-1221.	
C21	Boehm et al. (1997) "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Letters to Nature</u> , Vol. 390, pp. 404-407.	
C22	Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , Vol. 252, pp. 190-194.	
C23	Brooks et al. (1994), "Integrin $\alpha_5\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , Vol. 79, pp. 1157-1164.	
C24	Burgess et al., (1990), "Possible Dissociation of the heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , Vol. 111, pp. 2129-2138.	
C25	Canfield et al. (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , Vol. 173, No. 6, pp. 1483-1491.	
C26	Cao et al., (1996), "Kringle Domains of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , Vol. 271, No. 46, pp. 29461-29467.	
C27	Cao et al. (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , Vol. 272, No. 36, pp. 22924-22928.	
C28	Capon et al. (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , Vol. 337, pp. 525-531.	
C29	Chan et al., (1991) "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879.	
C30	Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , Vol. 5, pp. 385-90.	
C31	Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin" <u>Nature</u> , Vol. 339, pp. 394-397.	
EXAMINER		DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP: 1646
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C32	Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," <u>Nature</u> , Vol. 335, pp. 370-372.	
C33	Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , Vol. 159, No. 1, pp. 351-358.	
C34	Cheon et al. (1994) "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> 91: 989-993.	
C35	Cohen, S. L. et al., (August 15, 1996), "Human leptin characterization," <u>Nature</u> , Vol. 382, p. 589.	
C36	Cole et al. (1997) "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , Vol. 159, pp. 3613-3621.	
C37	Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , Vol. 56, pp. 2531-2534.	
C38	D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91, pp. 4082-4085.	
C39	D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , Vol. 176, pp. 1387-1398.	
C40	Ding et al., (September 1988), "Zinc-Dependent Dimers Observed in Crystals of Human Edostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , Vol. 95, No. 18, pp. 10443-10448.	
C41	Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , Vol. 161, pp. 156-166.	
C42	Eisenthal, (1990) "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> Vol. 31, pp. 342-348.	
C43	Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , Vol. 146, pp. 2446-2452.	
C44	Friedman, J. M. et al., (October 22, 1998). "Leptin and the regulation of body weight in mammals," <u>Nature</u> , Vol. 395, pp. 763-770.	
C45	Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils", <u>Science</u> , Vol. 226, pp. 1339-134.	
C46	Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses" <u>Annu. Rev. Immunol.</u> , Vol. 16, pp. 495-521.	
C47	Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist" <u>Eur. J. Immunol.</u> , Vol. 25, pp. 200-206.	
EXAMINER		DATE CONSIDERED

RECEIVED
MAY 05 2003
TECH CENTER
1600/2900

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP: 1646
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C48	Gillies et al. (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> Vol. 1, No. 1, pp. 47-54.	
C49	Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , Vol. 125, pp. 191-202.	
C50	Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , Vol. 89, pp. 1428-1432.	
C51	Gillies et al., (1989), "Expression of Human Anti-Tetanus toxoid antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , Vol. 7, pp. 799-804.	
C52	Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , Vol. 120, No. 6, pp. 2027-2032.	
C53	Goeddel et al., (1986), "Tumor Necrosis Factors; Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609.	
C54	Gren et al., (1983), "A New Type of Leukocytic Interferon,".. <u>Dokl. Biochem.</u> , Vol. 269, pp. 91-95.	
C55	Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , Vol. 73, No. 8, pp. 2081-2085.	
C56	Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> Vol. 45, pp. 146-148.	
C57	Harris et al., "Therapeutic Antibodies - the Coming of Age" <u>Tibtech</u> , 11:42-44 (Feb. 1993).	
C58	Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , Vol. 11, Issue 6, pp. 629-636.	
C59	He et al. (1998) "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunol.</u> 1029-1035.	
C60	Heijnen et al. (1996) "Antigen Targeting to Myeloid-specific Human FcYRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , Vol. 97, No. 2, pp. 331-338.	
C61	Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers" In Vivo Biology of IL-12 p40 Homodimer," <u>Journal of Immunology</u> , Vol. 158, pp. 4381-4388.	
EXAMINER		DATE CONSIDERED

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C62	Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 83, No. 18, pp. 7059-7063.	
C63	Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , Vol. 3, pp. 31-58.	
C64	Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , Vol. 7, No. 2, pp. 159-167.	
C65	Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1/5 Å Resolution," <u>EMBO Journal</u> , Vol. 17, No. 6, pp. 1656-1664.	
C66	Holden, et al. (2001) "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents." <u>Proceedings of the American Association for Cancer Research</u> , Vol. 42, p. 683.	
C67	Holden, et al. (2001) "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents" <u>Clinical Cancer Research</u> ; Vol. 7, No. 9, pp. 2862-2869.	
C68	Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , Vol. 1096, No. 4, pp. :345-354 (Abstract).	
C69	Hoogenboom et al., (1991), "Constriction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , Vol. 28, No. 9, pp. 1027-1037	
C70	Huck et al. (1986) "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," <u>Nucleic Acids Research</u> , Vol. 14, No. 4, pp. 1779-1789.	
C71	Huse et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , Vol. 246, pp. 1275-1281.	
C72	Ingber et al. (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , Vol. 348, pp. 555-557.	
C73	Jones et al., (1986) "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , Vol. 321, No. 6069, pp. 522-525.	
C74	Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, pp. 4479-4483.	
C75	Junghans et al. (1996) "The protection receptor of IgG catabolism is the B2-micorgobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, No. 11, pp. 5512-5516.	
C76	Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 88, pp. 11120-11123.	
EXAMINER		DATE CONSIDERED

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999
EXAM. INIT. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C77	Kappel, et al. (1992) "Regulating gene expression in transgenic animals," <u>Current Opinion in Biotechnology</u> 3:548-553
	C78	Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc λ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , Vol. 160, No. 6, pp. 1686-1701.
	C79	Kendra et al., (1999), "Pharmacokinetics and stability of the ch 14.18-interleukin-2 fusion protein in mice," <u>Cancer Immunol. Immunotherapy</u> , Vol. 48, pp. 219-229.
	C80	Kim, et al. (1999) "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV" <u>Journal of Interferon and Cytokine Research</u> , Vol. 19, pp. 77-84.
	C81	Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 81, 7922-7926.
	C82	Kuo, et al. (2001) "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , Vol. 152, No. 6, pp. 1233-1246.
	C83	LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , Vol. 268, No. 31, pp. 23311-23317.
	C84	Lazar et al., (1988), "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> Vol. 8, No. 3, pp. 1247-1252.
	C85	LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , Vol. 51, pp. 2694-2698.
	C86	Linsley et al. (1991) "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , Vol. 174, No. 3, pp. 561-569.
	C87	Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , Vol. 239, pp. 395-398.
	C88	Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 82, pp. 8648-8652.
	C89	Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , Vol. 92, No. 10, pp. 3730-3736.
	C90	Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells" <u>Protein Engineering</u> , Vol. 11, No. 6, pp. 495-500.
	C91	Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , Vol. 91, No. 5, pp. 1706-1715.
EXAMINER		DATE CONSIDERED

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP: 1646
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C92	Lode et al., (1999), "Synergy between an antiangiogenic integrin α_v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 1591-1596.	
C93	Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , Vol. 29, No. 2, pp. 117-120.	
C94	Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 8591-8596.	
C95	Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDE-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , Vol. 84, No. 8, pp. 2457-2466.	
C96	Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> Vol. 25, pp. 137-146.	
C97	Medesan et al. (1997) "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1 ¹ ," <u>Journal Immunology</u> , Vol. 158, No. 5, pp. 2211-2217.	
C98	Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , Vol. 57, pp. 2890-2895.	
C99	Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> Vol. 7, pp. 145-173.	
C100	Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, pp. 8258-8262.	
C101	Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , pp. 123-140.	
C102	Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , Vol. 13, No. 17, pp. 6361-6373.	
C103	Neuberger, et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , Vol. 312, pp. 604-608.	
C104	O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , Vol. 79, pp. 315-328.	
C105	O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , Vol. 2, No. 6, pp. 689-692.	
C106	O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , Vol. 88 pp. 277-285.	
EXAMINER	DATE CONSIDERED	

RECEIVED
MAY 05 2003
TECH CENTER
1600/2900

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999 GROUP: 1646
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C107	Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins", <u>Journal of Biological Chemistry</u> , Vol. 264, No. 26, pp. 15157-15160.	
C108	Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , Vol. 6, pp. 407-438.	
C109	Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , Vol. 163, pp. 166-178.	
C110	Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal Immunology</u> , Vol. 142, No. 10, pp. 3662-3667.	
C111	Putzer et al. (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , Vol. 94, pp. 10889-10894.	
C112	Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , Vol. 7. Suppl. 2, pp. S99-S106.	
C113	Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , Vol. 343, pp. 1177-1183.	
C114	Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , Third Edition.	
C115	Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , Vol. 9, No. 2, pp. 58-62.	
C116	Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> 2, Vol. 2, No. 3, pp. 159-173.	
C117	Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , Vol. 46, pp. 4701-4705.	
C118	Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , Vol. 17, No. 15, pp. 4249-4256.	
C119	Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 84, pp. 6904-6908.	
C120	Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , Vol. 148, No. 11, pp. 3433-3340.	
C121	Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 85, No. 13, pp. 4842-4846.	
C122	Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG mediates cytotoxicity by Human Monocytes that is enhanced by interferon- λ and is not blocked by human IgG," <u>Journal of Immunology</u> , Vol. 137, No. 11, pp. 3378-3382.	
EXAMINER		DATE CONSIDERED

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C123	Shiff et al., (1995), "Sulindac Sulfide, an Asprin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , Vol. 96, pp. 491-503.	
C124	Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 87, pp. 5322-5326.	
C125	Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , Vol. 57, pp. 1329-1334.	
C126	Stevenson et al., (1997), "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab'γ and Analogous Ligands," <u>Journal of Immunology</u> , Vol. 158, pp. 2242-2250.	
C127	Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , Vol. 302, pp. 305-309.	
C128	Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , Vol. 143, No. 8, pp. 2595-2601.	
C129	Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , Vol. 178, No. 2, pp. 661-667.	
C130	Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , Vol. 57, pp. 920-925.	
C131	<u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 th ed. 1999).	
C132	Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , Vol. 48, No. 5, pp. 1119-1123	
C133	Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , Vol. 242, pp. 1166-1168	
C134	Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , Vol. 84, pp. 4008-4027.	
C135	Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , Vol. 56, pp. 467-470.	
C136	Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , Vol. 44, pp. 681-687.	
C137	Verhoeven et al. (1988) "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> 239:1534-1536.	
EXAMINER		DATE CONSIDERED

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-003 APPLICANT(S): Gillies et al. SERIAL NO.: 09/256,156 FILING DATE: February 24, 1999
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
C138	Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein", <u>Protein Engineering</u> , Vol. 1, No. 6, pp. 493-498.	
C139	Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , Vol. 43, pp. 319-324.	
C140	Wooley et al. (1993) "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>J. Immunol.</u> 151: 6602-6607.	
C141	Wu et al., (July 1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin", <u>Biochemical and Biophysical Research Communications</u> , Vol. 236, No. 3, pp. 651-654.	
C142	Xiang et al. (1997) "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , Vol. 57, pp. 4948-4955.	
EXAMINER	DATE CONSIDERED	

2614877

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900